基因修饰表达抗B细胞成熟抗原嵌合抗原受体的T细胞使预后不良的复发性多发性骨髓瘤获得缓解
这项首次人体试验在16例既往中位9.5线治疗、63%对末线方案耐药的复发性多发性骨髓瘤患者中,于环磷酰胺联合氟达拉滨预处理后输注9×10^6/kg CAR-BCMA T细胞,总缓解率81%,63%达非常好的部分缓解或完全缓解,中位无事件生存31周;部分细胞因子释放综合征严重但可逆,并观察到BCMA抗原丢失。
要点
- 16例重度经治复发性多发性骨髓瘤患者输注9×10^6/kg CAR-BCMA T细胞,总缓解率81%。
- 63%达非常好的部分缓解或完全缓解,中位无事件生存31周,11例可评估微小残留病者均转阴。
- 部分细胞因子释放综合征严重但可逆,并观察到多发性骨髓瘤BCMA抗原丢失。
核心结论
- CAR-BCMA T细胞对重度经治的复发性/难治性多发性骨髓瘤具有显著活性,结果应鼓励进一步开发多发性骨髓瘤CAR T细胞疗法。
研究设计与样本
- 首次人体临床试验,报告试验最高剂量水平9×10^6/kg CAR-BCMA T细胞治疗的16例患者结果。
- 患者既往多发性骨髓瘤治疗中位9.5线,63%对入组前末线方案耐药。
- T细胞经编码CAR-BCMA的γ-逆转录病毒载体转导,输注前接受环磷酰胺联合氟达拉滨预处理化疗。
主要发现
- 总缓解率81%,其中63%达非常好的部分缓解或完全缓解。
- 中位无事件生存31周。
- 缓解包括广泛骨髓骨髓瘤清除和软组织浆细胞瘤消退。
- 11例获得部分缓解或更好抗骨髓瘤缓解且多发性骨髓瘤可评估微小残留病的患者均获得骨髓微小残留病阴性状态。
- 血CAR+细胞峰值水平高与抗骨髓瘤缓解相关;输注后6至9天血CAR-BCMA T细胞主要为高度分化的CD8+ T细胞;观察到多发性骨髓瘤BCMA抗原丢失。
关键数值与推荐
- 16例患者接受9×10^6 CAR-BCMA T细胞/kg(试验最高剂量水平)。
- 总缓解率81%,非常好的部分缓解或完全缓解率63%,中位无事件生存31周。
- 11例部分缓解或更好且微小残留病可评估者均达骨髓微小残留病阴性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 细胞因子释放综合征毒性部分病例严重但可逆。
- 观察到多发性骨髓瘤BCMA抗原丢失。
- 作者认为结果应鼓励进一步开发多发性骨髓瘤CAR T细胞疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM). T cells can be genetically modified to express chimeric antigen receptors (CARs), which are artificial proteins that target T cells to antigens. B-cell maturation antigen (BCMA) is expressed by normal and malignant plasma cells but not normal essential cells. We conducted the first-in-humans clinical trial, to our knowledge, of T cells expressing a CAR targeting BCMA (CAR-BCMA). Patients and Methods Sixteen patients received 9 × 106 CAR-BCMA T cells/kg at the highest dose level of the trial; we are reporting results of these 16 patients. The patients had a median of 9.5 prior lines of MM therapy. Sixty-three percent of patients had MM refractory to the last treatment regimen before protocol enrollment. T cells were transduced with a γ-retroviral vector encoding CAR-BCMA. Patients received CAR-BCMA T cells after a conditioning chemotherapy regimen of cyclophosphamide and fludarabine. Results The overall response rate was 81%, with 63% very good partial response or complete response. Median event-free survival was 31 weeks. Responses included eradication of extensive bone marrow myeloma and resolution of soft-tissue plasmacytomas. All 11 patients who obtained an anti-MM response of partial response or better and had MM evaluable for minimal residual disease obtained bone marrow minimal residual disease-negative status. High peak blood CAR+ cell levels were associated with anti-MM responses. Cytokine-release syndrome toxicities were severe in some cases but were reversible. Blood CAR-BCMA T cells were predominantly highly differentiated CD8+ T cells 6 to 9 days after infusion. BCMA antigen loss from MM was observed. Conclusion CAR-BCMA T cells had substantial activity against heavily treated relapsed/refractory MM. Our results should encourage additional development of CAR T-cell therapies for MM.
引用
- Brudno JN, Maric I, Hartman SD, et al. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. J Clin Oncol. 2018. PMID: 29812997. doi:10.1200/JCO.2018.77.8084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。